Introduction {#s0001}
============

The applications of natural compounds and medicinal plants to diseases are novel trends in clinical medicine research. Licorice is a very famous ancient herb, which is most frequently used in traditional Chinese medicine (TCM). In Chinese Pharmacopoeia, three original plants from the family Leguminosae, *Glycyrrhiza uralensis* Fisch., *G. inflata* Bat. and *G. glabra* L. are prescribed as licorice. The licorice cuts from the dry roots and rhizomes of licorice are widely used in clinical prescriptions ([Figure 1](#F0001){ref-type="fig"}). The pharmaceutical importance of licorice lies in their capacity to produce a great variety of secondary metabolites. Depending on the modern studies, the most important bioactive compounds in licorice are triterpenes, flavonoids and polysaccharides (Seki et al. [@CIT0072]; Zhu et al. [@CIT0097]). They have been reported with antitumor (Wang KL et al. [@CIT0082]; Li et al. [@CIT0052]), antimicrobial (Ahn et al. [@CIT0002]; Long et al. [@CIT0058]), antiviral (Kwon et al. [@CIT0047]; Feng et al. [@CIT0014]), anti-inflammatory (Chandrasekaran et al. [@CIT0007]; Wu et al. [@CIT0088]), antidiabetic (Mae et al. [@CIT0061]; Li et al. [@CIT0051]), immunoregulatory (Hong et al. [@CIT0031]; Li et al. [@CIT0053]), hepatoprotective (Abe et al. [@CIT0001]; Sharifzadeh et al. [@CIT0073]), neuro-protective activities (Zhao et al. [@CIT0096]; Michel et al. [@CIT0063]) and adrenal cortical hormone kind functions (Kageyama et al. [@CIT0039]; Raikkonen et al. [@CIT0069]).
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In recent years, inflammation responses with Celsus' four cardinal signs, namely calor (heat), dolor (pain), rubor (redness) and tumour (swelling) have attracted increasing attention (Fullerton & Gilroy [@CIT0020]). Inflammation responses play an important role in multiple diseases with a high prevalence among population, such as hepatitis (Matsuzaki et al. [@CIT0062]), lung disease (Yang H et al. [@CIT0093]) and Alzheimer's disease (Jayaraman et al. [@CIT0037]). And, they are also centrally related to the pathogenesis of a large number of acute and chronic diseases, such as rheumatoid arthritis (Yang CLH et al. [@CIT0092]), colonic inflammatory response (Takhshid et al. [@CIT0077]) and periodontitis (Farhad et al. [@CIT0013]). However, the conventional therapies for inflammation, including steroids and nonsteroid anti-inflammatory drugs (NSAID) (Sostres et al. [@CIT0075]; Parikh & Scadding [@CIT0067]; Carrasco-Pozo et al. [@CIT0006]), have shown many side effects and deficiencies. Considering this, licorice is an excellent alternative choice, due to the fact that it causes minimal disorders in the physiological functions of organism, has a nonspecific action and exerts a therapeutic action regardless of the direction of the pathological state. Furthermore, it is especially suitable for children, since glycyrrhizin (GC), a compound isolated from licorice, is 50 times sweeter than sugar that makes it much easier for children to accept (Liu et al. [@CIT0056]).

The present review aims to summarize the anti-inflammatory properties and mechanisms of licorice and its natural compounds, introduce the related clinical drugs, evaluate the safety and obtain new insights for further research of licorice.

Literature search {#s0002}
=================

The present review is intended to discuss past and current research on the anti-inflammatory activities of licorice and its natural products. With this objective, an extensive collection of scientific literature was examined by considering all highlighted research articles and reviews on the issue. Four main databases, PubMed, Web of Science, Science Direct and ResearchGate were used as information sources by the inclusion of the search terms 'licorice', 'licorice metabolites', 'anti-inflammatory', 'triterpenoids', 'flavonoids' and their combinations, mainly from the years 2010 to 2016 without language restriction. All the references were selected from Science Citation Index journals, *in vitro* studies with the Jadad score less than 2 points and *in vivo* and clinical studies with experimental flaws were excluded. As a result, we searched 295 papers and a total of 93 references were included in the present work.

Licorice applications in TCM therapeutics to treat inflammation {#s0003}
---------------------------------------------------------------

In TCM therapeutics, licorice has been used to strengthen the function of digestive system, eliminate phlegm, relieve coughing and alleviate pain since ancient times (Guo et al. [@CIT0026]). Licorice is honoured as the 'excellent coordinator' for harmonizing different ingredients, and regarded as 'guide drug' for helping the rapid absorption into bloodstream, organs and target cells (Wang X et al. 2013). In authoritative medical formulary in ancient China, it has been applied to treat respiratory, gastric and liver diseases, and also used to alleviate the toxicity of other drugs.

*Sanao* decoction, which consists of licorice, ephedra (the stem of *Ephedra sinica* Stapf, Mahuang in Chinese) and apricot seeds (the seeds of *Prunusarmeniaca* L. var*. ansu* Maxim, Xingren in Chinese), and *Jiegeng* decoction, which consists of licorice and *Platycodon grandiflorum* (the roots of *Platycodon grandiflorum* (Jacq.) A. DC., Jiegeng in Chinese), are used to treat the phlegm retention, cough and asthma. When acting as an agent for relaxing spasm, relieving pain and recovering the gastric ulcer, licorice is always combined with peony (the roots of *Paeonia lactiflora* Pall., Shaoyao in Chinese) in *Shaoyaogancao* decoction, with ginseng (the roots of *Panax ginseng* C. A. Mey., Renshen in Chinese), white atractylodes (the rhizome of *Atractylodes macrocephala* Koidz., Baizhu in Chinese) and poria (the sclerotium of *Poriacocos* (Schw.) Wolf, Fuling in Chinese) in *Sijunzi* decoction, and with scutellaria baicalensis (the roots of *Scutellaria baicalensis* Georgi, Huangqin in Chinese), peony and fructus ziziphi jujubae (the fructus of *Ziziphus jujuba* Mill., Dazao in Chinese) in *Huangqin* decoction. Above all, licorice has functions of eliminating phlegm, relieving cough, preventing asthma and recovering the gastric ulcer due to TCM theories for thousands of years.

With the development of Chinese traditional medicine modernization, the pharmacological mechanisms of Chinese medicine formula containing licorice were also investigated. The Chinese herbal formula *Sini Tang* decreased the expression of atrial natriuretic peptide levels in plasma and increased the vascular active marker nitric oxide (NO), which limited vascular inflammation (Liu et al. [@CIT0057]). *Shaoyaogancao* decoction suppressed clozapine metabolism in human liver microsomal system principally associated with the inhibition of related CYP activity (Wang et al. [@CIT0084]). When applied to HaCaT human keratinocyte cell line, it attenuated tumour necrosis factor-α (TNF-α) and interferon-γ-mediated chemokine production by targeting the STAT1 and nuclear factor-kappa B (NF-κB) signalling in keratinocytes (Jeong et al. [@CIT0038]). In the 2,4,6-trinitrobenzenesulfonic acid-induced colitis mice models, the level of colonic myeloperoxidase (MPO) activity and the tissue levels of TNF-α, interleukin-1β (IL-1β) and IL-6 were markedly decreased after the gavage of *Huangqin* decoction (Bi et al. [@CIT0004]). All the above suggest that many Chinese formulas containing licorice could serve as a therapeutic drug candidate for the treatment of inflammatory diseases.

Anti-inflammatory activities of licorice extracts {#s0004}
-------------------------------------------------

Thus far, reports about the anti-inflammatory activity of licorice extracts concentrated mainly on *G. glabra* and *G. uralensis* ([Table 1](#t0001){ref-type="table"}). *Glycyrrhiza glabra* has been used to treat gastric ulcer, oral ulcer (Liu et al. [@CIT0056]) and ulcerative colitis (Samadnejad et al. [@CIT0071]). *Glycyrrhiza glabra* reduced the ulcer zone, and is a good choice for children who do not like taking bitter medicines *[(]{.smallcaps}*Liu et al. [@CIT0056]). It attenuated macroscopic damage, improved the microscopic structure of the colonic mucosa, and effectively increased superoxide dismutase (SOD) enzymatic defence system to treat acetic acid-induced ulcerative colitis. Furthermore, TNF-α, NO and IL-6 levels were also diminished dose-dependently (*p* \< 0.05) (Samadnejad et al. [@CIT0071]).

###### 

The anti-inflammatory activities of licorice extracts.

  Species          Solvent   Inflammation tissue/disease                                        Model formation                        Extract concentration   Inhibition rate                                                             Toxic signs/mortality   Reference
  ---------------- --------- ------------------------------------------------------------------ -------------------------------------- ----------------------- --------------------------------------------------------------------------- ----------------------- ----------------------------------
  *G. glabra*      Acetone   LPS (0.1 μg·mL^−1^)- induced J774A.1 murine macrophage cell line   Stimulation with LPS (0.1μg·mL^−1^).   20--40 μg·mL^−1^        Dose-dependently inhibit IL-1β, up to 47.8%                                                         (Thiyagarajan et al. [@CIT0079])
  *G. uralensis*   Ethanol   The murine RAW264.7 macrophage cells                               Stimulation with LPS (1 μg·mL^−1^)     25 μg·mL^−1^            Inhibit LPS-induced NO production (*p*\<0.001) by 48%                                               (Wu et al. [@CIT0088])
  *G. uralensis*   Ethanol   Human colon cancer cells HT-29 (HT-29-N9)                          Stimulation with LPS (1 μg·mL^−1^)     25 μg·mL^−1^            Suppress the LPS-induced NF-κB luciferase activity (*p*\<0.05)                                      (Wu et al. [@CIT0088])
  *G. uralensis*   Ethanol   Human hepatoma HepG2 cell (HepG2-C8)                               Stimulation with LPS (1 μg·mL^−1^)     25 μg·mL^−1^            Induce the luciferase activity in HepG2C8 cells by fourfolds (*p*\<0.001)                           (Wu et al. [@CIT0088])

*Glycyrrhiza uralensis* has been applied to lipopolysaccharide (LPS)-treated Raw264.7 macrophages and mouse skin treated with 12-*O*-tetradecanoylphorbol-13-acetate (TPA) *in vitro*. In LPS-treated Raw264.7 macrophages model, *G*. *uralensis* reduced NO and prostaglandin E2 (PGE2) release, the secretion and mRNA levels of TNF-α, IL-6, cyclooxygenase-2 (COX-2) and IL-1β, the protein expression and transcriptional activity of inducible nitric oxide synthase (iNOS) and phospholipase A2 (PLA2) (Wu et al. [@CIT0088]). It also prevented the inhibitor of NF-κB α (IκBα) degradation and p65 nuclear translocations. In the mouse inflammation model, it suppressed skin swelling and the expression of iNOS and COX-2 (Cho HJ et al. [@CIT0009]).

Anti-inflammatory active compounds of licorice {#s0005}
----------------------------------------------

The three original plants of licorice are *G. uralensis*, *G. inflata* and *G. glabra*. They contain many natural active compounds, including more than 20 triterpenes and 300 flavonoids. Seventy-three bioactive compounds and 91 potential targets are identified for this medicinal herb (Li et al. [@CIT0054]; Liu et al. [@CIT0055]). Among them, 3 triterpenes, 18β-GC, 18α-GC and 18β-glycyrrhetinic acid (18β-GA), and 13 flavonoids, licochalcone A (LCA), licochalcone B (LCB), licochalcone C (LCC), licochalcone D (LCD), licochalcone E (LCE), isoliquiritigenin (ISL), echinatin (EC), glabridin (GLD), isoangustone A (ISOA), licoricidin (LID), licorisoflavan A (LIA), dehydroglyasperin C (DGC) as well as dehydroglyasperin D (DGD), all have been reported to possess anti-inflammatory activity. The large number of metabolites indicated that licorice was an ideal option for obtaining anti-inflammation compounds. The chemical structure formulas of the above compounds are shown in [Figure 2](#F0002){ref-type="fig"}. Furthermore, in order to have a full appreciation of these active compounds, all available data related to *in vitro* anti-inflammatory activities referring to 16 compounds in 52 assays are shown in [Table 2](#t0002){ref-type="table"}. Similarly, in [Table 3](#t0003){ref-type="table"}, we focussed on the anti-inflammatory activities of these natural compounds *in vivo*, thus, recent investigations of 6 compounds and 10 assays have been collected. The inflammation tissues, cell lines and animal models, dosage of drugs, inhibition rates, detective methods and the toxic signs are all listed in detail.

###### 

The chemical structure formulas of compounds with anti-inflammatory activity in licorice.
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###### 

The anti-inflammatory properties of licorice compounds *in vitro*.

  Compounds   Inflammation tissue/disease                                           Cell                                                                                    Concentration                                                 Inhibition rate                                                                                                                              Method                                                           Toxic signs/mortality                                                                       Reference
  ----------- --------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------
  18β-GC      LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         75 μM                                                         51% reduction in NO                                                                                                                          ELISA                                                            Do not affect the viability of the RAW 264.7 cells at the concentration lower than 200 μM   (Wang et al. [@CIT0081])
  18β-GC      LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         75 μM                                                         49% reduction in PGE2                                                                                                                        ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  18β-GC      LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         75 μM                                                         46% reduction in TNF-α                                                                                                                       ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  18β-GC      LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         75 μM                                                         42% reduction in IL-6.                                                                                                                       ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  18β-GC      LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         75 μM                                                         51% reduction in IL-1β                                                                                                                       ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  18β-GC      *Leishmania donovani-*infected macrophages                            Peritoneal macrophages of *Leishmania donovani*-infected BALB/c mice (4--6 weeks old)   50 mg·mL^−1^                                                  90.94% reduction in the parasite load                                                                                                        ELISA                                                            Optimal viability at mg·mL^−1^ showing 88% survival                                         (Bhattacharjee et al. [@CIT0003])
  18α-GC      Ischaemia/reperfusion in L02 cells                                    The human hepatic L02 cell line                                                         10 mg·mL^−1^                                                  Increase the activities of SOD and GSH-Px                                                                                                    SOD and GSH-Px Detection Kits                                                                                                                                (Huang et al. [@CIT0033])
  18α-GC      LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW264.7 macrophages                                                                    0.5 mg·mL^−1^ or 1 mg·mL^−1^                                  Suppress PGE2, PGI2, TXB2 and LTB4                                                                                                           ELISA                                                                                                                                                        (Xie et al. [@CIT0090])
  18β-GA      Indomethacin-induced small intestinal damage                                                                                                                  Complex compound of 18β-GA and hydroxypropyl-γ-cyclodextrin   Reduce mRNA expressions of TNF-α, IL-1β and IL-6                                                                                                                                                                                                                                                          (Ishida [@CIT0036])
  18β-GA      LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         75 μM                                                         34% reduction in NO                                                                                                                          ELISA                                                            Do not affect the viability of the RAW 264.7 cells at the concentration lower than 150 μM   (Wang et al. [@CIT0081])
  18β-GA                                                                                                                                                                    75 μM                                                         58% reduction in PEG2                                                                                                                        ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  18β-GA                                                                                                                                                                    75 μM                                                         34% reduction in TNF-α                                                                                                                       ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  18β-GA                                                                                                                                                                    75 μM                                                         35% reduction in IL-6                                                                                                                        ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  18β-GA                                                                                                                                                                    75 μM                                                         42% reduction in IL-1β                                                                                                                       ELISA                                                                                                                                                        (Wang et al. [@CIT0081])
  LCA         TNFα (10 ng·mL^−1^)-induced NF-κB activation                          NIH-3T3 cells                                                                           10/20/30 μM                                                   Inhibit in a dose-dependent manner                                                                                                           EMSA                                                                                                                                                         (Funakoshi-Tago et al. [@CIT0021])
  LCA         LPS (1 μg·mL^−1^)-induced mouse peritoneal macrophage cells           Mouse peritoneal macrophage cells                                                       0.1/0.5/1 μg·mL^−1^                                           Decrease PGE2 by 31.1, 58.3 and 80.3%                                                                                                        PGE2 kit                                                                                                                                                     (Cui et al. [@CIT0012])
  LCA         LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         10 μM.                                                        The PGE2 inhibition rates exceed 80%                                                                                                         DCFH-DA fluorometric assay                                                                                                                                   (Fu et al. [@CIT0018])
  LCA         LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         12.8 ± 1.45 μM.                                               The effective concentration of ABTS^+^ radicals are scavenged by 50%                                                                         ABTS + radical scavenging capacity assay                                                                                                                     (Fu et al. [@CIT0018])
  LCA         LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         11.6 ± 1.84 μM                                                Inhibitory activity on lipid peroxidation EC50                                                                                               Fe2^+^-ascorbic acid system                                                                                                                                  (Fu et al. [@CIT0018])
  LCB         LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         3 μM.                                                         The inhibition rate of NO exceeds 50%.                                                                                                       DCFH-DA fluorometric assay                                                                                                                                    
  LCB         LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         2.68 ± 0.09 μM.                                               The concentration of ABTS^+^ radicals are scavenged by 50%                                                                                   ABTS^+^ radical scavenging capacity assay                                                                                                                    (Fu et al. [@CIT0018])
  LCB         LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         3.92 ± 0.12 μM                                                Inhibitory activity on lipid peroxidation EC50                                                                                               Fe^2+^-ascorbic acid system                                                                                                                                  (Fu et al. [@CIT0018])
  LCC         RBL-2H3 cells sensitized with anti-DNP IgE (100 ng·mL^−1^)            RBL-2H3 cells                                                                           24 μM                                                         Inhibition of β-hexosaminidase release                                                                                                       β-hexosaminidase release assay and trypan blue exclusion assay   30% cytotoxicity: \> 30 μM                                                                  (Tanifuji et al. 2010)
  LCD         RBL-2H3 cells sensitized with anti-DNP IgE (100 ng·mL^−1^)            RBL-2H3 cells                                                                           21 μM                                                         Inhibition of β-hexosaminidase release                                                                                                       β-hexosaminidase release assay and trypan blue exclusion assay   30% cytotoxicity: \> 30 μM                                                                  (Tanifuji et al. 2010)
  LCE         LPS-stimulated RAW 264.7 murine macrophage                            RAW 264.7 murine macrophage                                                             2.5--7.5 μmol·L^−1^                                           Dose-dependently inhibit NO, PGE2; markedly suppress the expression of iNOS and COX-2 proteins; and the secretion of IL-6, IL-1β and TNF-α   ELISA                                                                                                                                                        (Lee et al. [@CIT0050])
  Echinatin   LPS (1 μg·mL^−1^)-induced murine RAW 264.7 cells                      RAW 264.7 cells                                                                         2.95 ± 0.11 μM                                                The effective concentration of ABTS^+^ radicals are scavenged by 50%                                                                         ABTS^+^ radical scavenging capacity assay                                                                                                                    (Fu et al. [@CIT0018])
  Echinatin                                                                                                                                                                 47.2 ± 2.64 μM                                                Inhibitory activity on 50% lipid peroxidation                                                                                                Fe^2+^-ascorbic acid system                                                                                                                                  (Fu et al. [@CIT0018])
  ISL         LPS (0.1 μg·mL^−1^)-induced J774A.1 murine macrophage cell line       J774A.1 murine macrophage cell line                                                     2.5--10 μg·mL^−1^                                             NO levels with 50% inhibition attain at 7.5 μg·mL^−1^ (29 μM).                                                                               ELISA                                                                                                                                                        (Thiyagarajan et al. [@CIT0079])
  ISL         LPS (0.1 μg·mL^−1^)-induced J774A.1 murine macrophage cell line       J774A.1 murine macrophage cell line                                                     1.85 μg·mL^−1^ (7.2 μM)                                       IL-1 levels with 50% inhibition                                                                                                              ELISA                                                                                                                                                        (Thiyagarajan et al. [@CIT0079])
  ISL         LPS (0.1 μg·mL^−1^)-induced J774A.1 murine macrophage cell line       J774A.1 murine macrophage cell line                                                     1.92 μg·mL^−1^ (7.16 μm)                                      IL-6 levels with 50% inhibition                                                                                                              ELISA                                                                                                                                                        (Thiyagarajan et al. [@CIT0079])
  ISL         PMA (50 ng·mole^−1^)-exposed human umbilical vein endothelial cells   Human umbilical vein endothelial cells                                                  10 μM                                                         Nearly abolish the expression of MMP-2 mRNA                                                                                                  MTT                                                              Nontoxic concentrations showed up 25 ≤ μM for 24h serum-free culture experiments            (Kang et al. [@CIT0040])
  GLD         LPS (0.1 μg·mL^−1^)-induced J774A.1 murine macrophage cell line       J774A.1 murine macrophage cell line                                                     10 μg·mL^−1^                                                  33% inhibition in NO levels                                                                                                                  ELISA                                                                                                                                                        (Thiyagarajan et al. [@CIT0079])
  GLD         LPS (0.1 μg·mL^−1^)-induced J774A.1 murine macrophage cell line       J774A.1 murine macrophage cell line                                                     10 μg·mL^−1^ (30.8 μM)                                        IL-1 levels with 50% inhibition                                                                                                              ELISA                                                                                                                                                        (Thiyagarajan et al. [@CIT0079])
  LIA         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic leukaemia cell line                      0.1, 0.5, 1 μg·mL^−1^                                         Decreased the secretion of IL-6                                                                                                                                                                               No obvious cytotoxic effects were detected at 1mg·mL^−1^ with the cell viability of 85%     (La et al. [@CIT0049])
  LIA         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic leukaemia cell line                      1 μg·mL^−1^                                                   Decreased the secretion of CCL5                                                                                                                                                                                                                                                                           (La et al. [@CIT0049])
  LIA         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic leukemia cell line                       0.1, 0.5, 1 μg·mL^−1^                                         Decreased the secretion of MMP-8                                                                                                                                                                                                                                                                          (La et al. [@CIT0049])
  LIA         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic leukaemia cell line                      0.5, 1 μg·mL^−1^                                              Decreased the secretion of MMP-7                                                                                                                                                                                                                                                                          (La et al. [@CIT0049])
  LIA         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic leukaemia cell line                      1 μg·mL^−1^                                                   Decreased the secretion of MMP-9                                                                                                                                                                                                                                                                          (La et al. [@CIT0049])
  LID         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic leukaemia cell line                      0.1, 0.5, 1 μg·mL^−1^                                         Decreased the secretion of IL-6                                                                                                                                                                               No obvious cytotoxic effects were detected at 1mg·mL^−1^ with the cell viability of 85%     (La et al. [@CIT0049])
  LID         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic *[leukaemia c]{.smallcaps}*ell line      0.1, 0.5, 1 μg·mL^−1^                                         Decreased the secretion of MMP-7 and MMP-8                                                                                                                                                                                                                                                                (La et al. [@CIT0049])
  LID         LPS (0.1 μg·mL^−1^)-induced U937 cells line                           U937 cells (ATCC CRL-1593.2; human monoblastic leukaemia cell line                      0.5, 1 μg·mL^−1^                                              Decreased the secretion of MMP-9                                                                                                                                                                                                                                                                          (La et al. [@CIT0049])
  DGC                                                                                                                                                                       0.5 mM                                                        Ferric reducing antioxidant power 855.07 ± 84.14 μmole·L^−1^                                                                                 Ferric reducing antioxidant power assay                                                                                                                      (Kim HJ et al. [@CIT0043])
  DGC                                                                                                                                                                       0.205 ± 0.005 mM                                              IC~50~ for DPPH                                                                                                                              DPPH radical scavenging assay                                                                                                                                (Kim HJ et al. [@CIT0043])
  DGC                                                                                                                                                                       0.465 ± 0.081 mM                                              IC~50~ value for ABTS^+^                                                                                                                     ABTS^+^ radical cation-*[decolourization]{.smallcaps}* assay                                                                                                 (Kim HJ et al. [@CIT0043])
  DGC         Glutamate (5 mM)-induced HT22 cells                                   HT22 cells                                                                              2 μM                                                          Dose-dependently inhibit ROS production                                                                                                      2,7-dichlorofluorescein (DCF) assay and western-blot                                                                                                         (Kim HJ et al. [@CIT0042])
  DGD                                                                                                                                                                       0.5 mM                                                        Ferric reducing antioxidant power 812.04 ± 40.35 μmole·L^−1^                                                                                 Ferric reducing antioxidant power assay                                                                                                                      (Kim HJ et al. [@CIT0043])
  DGD                                                                                                                                                                       0.309 ± 0.002 mM                                              IC50 for DPPH                                                                                                                                DPPH radical scavenging assay                                                                                                                                (Kim HJ et al. [@CIT0043])
  DGD                                                                                                                                                                       0.635 ± 0.035 mM                                              IC50 value for ABTS^+^                                                                                                                       ABTS^+^ radical cation-decolourization assay                                                                                                                 (Kim HJ et al. [@CIT0043])
  ISOA                                                                                                                                                                      0.5 mM                                                        Ferric reducing antioxidant power 231.57 ± 24.44 μmole·L^−1^                                                                                 Ferric reducing antioxidant power assay                                                                                                                      (Kim HJ et al. [@CIT0043])
  ISOA                                                                                                                                                                      0.418 ± 0.015 mM                                              IC~50~ for DPPH                                                                                                                              DPPH radical scavenging assay                                                                                                                                (Kim HJ et al. [@CIT0043])
  ISOA                                                                                                                                                                      0.655 ± 0.042 mM                                              IC~50~ value for ABTS^+^                                                                                                                     ABTS^+^ radical cation-decolourization assay                                                                                                                 (Kim HJ et al. [@CIT0043])

###### 

The anti-inflammatory properties of licorice compounds *in vivo*.

  Compounds   Inflammation tissue/disease                                                                                                  Models                                               Treatment                                              Outcomes                                                                                                   Reference
  ----------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------- ---------------------------
  18β-GC      An intratracheal instillation of LPS (1 mg·kg^−1^)                                                                           Male BALB/C mice weighing 20--25 g                   Intraperitoneal injection of 10, 25 and 50 mg·kg^−1^   Markedly decrease the MPO activity and NO concentrations                                                   (Ni et al. [@CIT0065])
              Injection of 0.94 nmole (0.2 μg) of kainic acid (KA)-induced neuronal death model                                            Male BALB/c mice (25-30 g)                           Intraperitoneal injection of 10 or 50 mg·kg^−1^        Iβ-1-positive cells are almost completely suppressedby 50 mg·kg^−1^18β-GC                                  (Luo et al. [@CIT0059])
  18α-GC      20% paraquat poisoning solution at 15 mg·kg^−1^ dose                                                                         30 male Sprague Dawley rats from 180 g to 200 g      Intraperitoneal injection of 30 mg·kg^−1^              Significantly decrease intercellular adhesion molecule-1 (ICAM-1) and matrix metalloproteinase-9 (MMP-9)   (Xiao et al. [@CIT0089])
  LCA         Noninfectious mouse model of asthma                                                                                          BALB/c mice                                          50 mg·kg^−1^                                           Inhibit the increase in T-helper type 2 cytokines, reduce serum levels of ovalbumin-specific IgE and IgG   (Chu et al. [@CIT0011])
              Topical inflammation was instantly induced on the posterior surface of the same ear by the application of xylene (0.05 mL)   Kunming mice 20--25 g and Wistar rats (150--200 g)   5 mg·kg^−1^                                            Decrease the ear oedema rate by30.3%                                                                       (Cui et al. [@CIT0012])
              0.1 mL freshly prepared carrageenan was injected into the right hind paw                                                     Kunming mice 20--25 g and Wistar rats (150--200 g)   2.5, 5 and 10 mg·kg^−1^ body weight                    Dose-dependentreduce the paw oedema rateby 41.3, 39.7 and 30.7%, respectively                              (Cui et al. [@CIT0012])
  LCE         5 nmoles of TPA 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse ear oedema                                          ICR mice                                             0.5--2 mg                                              Dose-dependently reduce the TPA-induced increase in ear weight and ear thickness                           (Lee et al. [@CIT0050])
  ISL         Male, 5-week-old C57BL/6 mice were fed a HFD containing 60% fat                                                              C57BL/6 mice                                         10 μM                                                  Inhibit HFD-induced IL-1 and caspase-1 production                                                          (Honda et al. [@CIT0032])
  GLD         5% dextran sulphate sodium-induced BALB/c mice                                                                               BALB/c mice                                          10 or 50 mg·kg^−1^                                     Attenuate mortality, loss of body weight, shortening of the colon and severe clinical symptoms.            (Kwon et al. [@CIT0048])

Triterpenes and related possible mechanisms for inflammation prevention {#s0006}
=======================================================================

More than 20 triterpenes have been isolated from the roots of licorice, but only 18β-GC, 18α-GC and 18β-GA, have been reported to possess the anti-inflammatory activity. The possible mechanisms for the inflammation prevention of the three triterpenes and the inflammatory types were investigated as follows.

18β-Glycyrrhizin {#s0007}
----------------

18β-GC is regarded as the marker compound in licorice. It has been demonstrated that 18β-GC suppressed MPO activity (Ni et al. [@CIT0065]) and phosphorylation and secretion of high mobility group protein 1 (Kim SW et al. [@CIT0046]). It also decreased the levels of cholesterol of lipid rafts, the translocation of toll-like receptor 4 to lipid rafts and the interferon regulating factor 3 activation (Fu et al. [@CIT0019]). Furthermore, it attenuated the production of PGE2, intracellular reactive oxygen species (ROS), TNF-α, COX-2 and iNOS (Luo et al. [@CIT0059]). Moreover, 18β-GC also activated ATP-binding cassette transporter A1, which induced cholesterol efflux from lipid rafts (Fu et al. [@CIT0019]).

Thus far, 18β-GC has been applied to LPS-stimulated macrophage models (Wang et al. [@CIT0081]), mouse mammary epithelial cells (Fu et al. [@CIT0019]) and *Leishmania donovani*-infected macrophages (Bhattacharjee et al. [@CIT0003]) *in vitro*, and been applied to the postischaemic brain rats models (Kim SW et al. [@CIT0046]; Luo et al. [@CIT0059];), LPS-induced mastitis rat models (Fu et al. [@CIT0019]) and LPS-induced acute lung injury (ALI) rat models *in vivo*. It can also suppress microglia activation, the mammary gland histopathological changes and LPS-induced alveolar haemorrhage (Ni et al. [@CIT0065]).

18α-Glycyrrhizin {#s0008}
----------------

18α-GC and 18β-GC is a pair of epimers, differed only in the C~18~-H. The anti-inflammatory activities of 18α-GC have been affirmed. It suppressed PLA2/arachidonic acid pathway metabolites, such as PGE 2, prostacyclin 2, thromboxane 2 and leukotrienes B~4~ (Xie et al. [@CIT0090]). It significantly reduced the content of intercellular adhesion moledule-1 and MMP-9 (Xiao et al. [@CIT0089]). What's more, it increased the activities of SOD and GSH-Px, and the expression of p-Akt and p-ERK (Huang et al. [@CIT0033]).

It has been reported that the protective and anti-inflammatory effects of 18α-GC were better than 18β-GC (Zeng et al. [@CIT0095]). It has been applied to RAW264.7 macrophages (Xie et al. [@CIT0090]), human ischaemia/reperfusion injury hepatic L02 cells (Huang et al. [@CIT0033]) *in vitro*, and paraquat poisoning-induced lung injury rat models (Xiao et al. [@CIT0089]) *in vivo.*

18β-Glycyrrhetinic acid {#s0009}
-----------------------

18β-GA is a hydrolyzed metabolite of 18β-GC. Since 18β-GC can generate 18β-GA through metabolic processes in the human body, the pharmacological effects of 18β-GA are essentially the same as 18β-GC. 18β-GA exerted its anti-inflammatory activities via inducing antioxidant defence systems, decreasing lipid peroxidations, ameliorated oxidative and histological damage. It also significantly reduced the generation of excessive NO, PGE2 and ROS, inhibited the protein and mRNA levels of iNOS and COX-2 and suppressed the release of LPS-induced TNF-α, IL-6 and IL-1β in a dose-dependent manner (Wang et al. [@CIT0081]; Ishida et al. [@CIT0036]). It has been studied in indomethacin-induced small intestinal damage (Ishida et al. [@CIT0036]), LPS-induced macrophages (Wang et al. [@CIT0081]) *in vitro* and neuronal damage caused by global cerebral ischaemia/reperfusion in C57BL/J6 mouse models (Oztanir et al. [@CIT0066]) *in vivo*, and the anti-inflammatory actions were significantly affirmed.

Flavonoids and related mechanisms for inflammation prevention {#s0010}
=============================================================

About 300 polyphenols have been isolated from licorice, including phenolic acids, flavonoids, flavans, chalcones, isoflavan and isoflavonoids. Thus far, the main anti-inflammatory active polyphenols in licorice are chalcones, isoflavan and isoflavonoids. Among them, chalcones, such as LCA, LCB, LCC, LCD, LCE, ISL and EC, isoflavonoids, such as ISOA, and isoflavan, such as GLD, LID, LIA, DGC and DGD have shown the potential as anti-inflammatory drugs.

Chalcones {#s0011}
---------

Chalcones include LCA, LCB, LCC, LCD, LCE, ISL and EC. The special scaffold of chalcones was regarded as the key factor for their broad biological activities (Karthikeyan et al. [@CIT0041]). It is believed that the fixed structure of LCA is necessary for its anti-inflammatory activity, since α,β-unsaturated ketone reduced LCA, which lacks a double bond, failed to inhibit TNFα-induced NF-κB activation. Furthermore, LCA markedly inhibited acute carrageenan-induced paw oedema in mice while the reduced LCA failed (Funakoshi-Tago et al. [@CIT0022], [@CIT0021]).

The mechanisms for the anti-inflammatory activities of chalcones have been fully investigated. LCA, LCB, ISL and EC all inhibited the production of NO, IL-6 and PGE2, while LCA, LCB and LCD all exhibited potent inhibition of lipid peroxidation (Haraguchi et al. [@CIT0027]; Thiyagarajan et al. [@CIT0079]; Fu et al. [@CIT0018]; Honda et al. [@CIT0032]). LCB and EC both showed strong scavenging activity towards the 2, 2′-azinobis-(3-ethylbenzthiazoline-6-sulphonate) (ABTS) (+) radical. LCB and LCD both strongly inhibited superoxide anion production in the xanthine oxidase system, showed potent scavenging activity on DPPH radical and inhibited phosphorylation of NF-κB p65 (Haraguchi et al. [@CIT0027]; Furusawa et al. [@CIT0024]). Furthermore, LCA significantly inhibited the release of cytokines, such as IL-4, IL-5 and IL-13, and serum levels of ovalbumin-specific immunoglobulin E (IgE), IgG. It also reduced the mRNA expression of acidic mammalian chitinase, chitinase 3-like protein 4, E-selectin, Muc5ac, CCl~11~ and CCR~3~ in lung tissues (Chu et al. [@CIT0011]). LCC decreased the expression and activity of iNOS, and modulated the antioxidant network activity of SOD, catalase and glutathione peroxidase (Wang et al. [@CIT0085]). LCD inhibited the mast cell degranulation through the inhibition of both extracellular Ca^2+ ^influx and activation of the MEK-ERK pathway (Tanifuji et al. 2010; Kim & Jun 2013). LCE effectively inhibited PKC/JNK, ERK1/2, reduced the expression of iNOS, COX-2, IL-6, IL-1β, IL-12p40, TNF-α, AKT and p38 mitogen-activated protein kinase (MAPK), and attenuated IκBα degradation and NF-κB activities, as well as transcriptional activity of activator protein AP-1 (Cho et al. [@CIT0010]; Lee et al. [@CIT0050]). ISL dampened the expression of MMP-2 mRNA in a dose-response manner, and at ≥10 μM, the expression was nearly abolished (Kang et al. [@CIT0040]).

For studies *in vitro*, LCA, LCB, LCC, LCD, LCE and EC has been applied to LPS-induced RAW264.7 mouse macrophage cell models and rat liver microsomes (Cui et al. [@CIT0012]; Fu et al. [@CIT0018]). LCD has been studied in rat baso-leukaemia (RBL)-2H3 cells, and ISL has been applied to LPS-induced J774A.1 murine macrophages cells models and human umbilical vein endothelial cells (Kang et al. [@CIT0040]; Thiyagarajan et al. [@CIT0079]).

For studies *in vivo*, LCA attenuated allergic airway inflammation in a murine model of asthma (Chu et al. [@CIT0011]), inhibited xylene-induced mice ear oedema and carrageenan-induced paw oedema (Cui et al. [@CIT0012]). LCE has been studied in TPA-induced mouse ear oedema models and oxazolone-induced chronic allergic contact dermatitis mouse skin model*s* (Cho YC et al. [@CIT0010]; Lee et al. [@CIT0050];). *In vivo* analyses also revealed that ISL potently attenuated high-fat-diet-induced obesity, hypercholesterolaemia and insulin resistance, which indicated that ISL could be useful for the treatment of NLRP3 inflammasome-associated diseases (Honda et al. [@CIT0032]).

Depending on some clinical studies, LCA had a similar effect to moderate childhood atopic dermatitis in comparison with 1% hydrocortisone. The transepidermal water loss was significantly lower than baseline, and the use of LCA for four weeks could maintain clinical improvement (Wananukul et al. [@CIT0080]).

Other flavonoids {#s0012}
================

Besides chalcones, other flavonoids in licorice, including DGC, DGD, ISOA, GLD, LID and LIA, also showed excellent anti-inflammatory activities. DGC, DGD and ISOA all showed strong ferric reducing activities and effectively scavenged DPPH, ABTS + and singlet oxygen radicals (Kim HJ et al. [@CIT0043]). Furthermore, DGC increased the expression of haemeoxygenase-1 and MAPK phosphatase-1, suppressed the inflammation-mediated neurodegeneration, production of TNF-α, NO, ROS, NF-κB and phosphorylation of p38 MAPKs, ERK1/2, IκB-α and p65 (Kim HJ et al., [@CIT0042]; Kim et al. [@CIT0044]). GLD significantly inhibited NO and IL-1β release (Thiyagarajan et al. [@CIT0079]), attenuated colonic inflammation in mice with dextran sulphate sodium-induced colitis (Kwon et al. [@CIT0048]), and decreased the iNOS mRNA expression under high-glucose levels, which indicated that GLD could be applied to diabetes-related vascular dysfunction (Yehuda et al. [@CIT0094]). LID and LIA inhibited the secretion of IL-6, chemokine (C-C motif) ligand 5, MMP-7, -8 and -9. The suppression of cytokine and MMP secretion by LID and LIA was associated with the reduced activation of NF-κB p65 in periodontitis treatment (La et al. [@CIT0049]).

*In vitro*, the anti-inflammatory activities of DGC, DGD and ISOA have been demonstrated in glutamate-induced mouse hippocampal HT22 cells models (Kim HJ et al. [@CIT0042]). DGC, GLD, LID and LIA have been used in LPS-treated Raw264.7 macrophages models (La et al. [@CIT0049]; Thiyagarajan et al. [@CIT0079]). DGC has also been applied to LPS-stimulated BV-2 microglia models (Kim et al. [@CIT0044]). And GLD has been applied in macrophage-like cells models under chronic glucose stress (Yehuda et al. [@CIT0094]). *In vivo*, GLD has been used in dextran sulphate sodium-induced colitis mice models (Kwon et al. [@CIT0048]).

The summary of main anti-inflammatory mechanisms of licorice {#s0013}
============================================================

Depending on previous studies, we found that decreasing the inflammatory factors was the key strategy for licorice to treat inflammation-related disease, such as rheumatoid arthritis (Yang et al. [@CIT0092]), liver oxidative injury (Huo et al. [@CIT0034]), colonic inflammatory response (Takhshid et al. [@CIT0077]) and periodontitis (Farhad et al. [@CIT0013]). Tumour necrosis factor, MMPs, PGE2 and free radicals are four main factors most widely reported among numerous studies related to licorice's anti-inflammatory mechanisms.

Tumour necrosis factor {#s0014}
----------------------

The role of TNF-α played in the progress of inflammation has been explored deeply. TNF-α is an autocrine stimulator as well as a potent paracrine inducer of pro-inflammatory mediators including IL-1, IL-6, IL-8 (Suzuki et al. [@CIT0076]) and granulocyte-macrophage colony-stimulating factor (Haworth et al. [@CIT0029]). Additionally, TNF-*α* stimulates chondrocytes to release MMPs in rheumatoid arthritis and periodontitis patients (Sorsa et al. [@CIT0074]). Furthermore, TNF-*α* also induces NO production and releases PGE2 by synovial cells, which in turn causes tissue destruction (Nagy et al. [@CIT0064]). Recently, treatment of ulcerative colitis with TNF-*α* antibody has achieved encouraging results in the clinic (Takhshid et al. 2002). In the progressive accumulation of liver fibrosis, the progress is triggered by a series of chemical mediators, with a prominent role played by the TNF-*β* (Poli [@CIT0068]). Depending on the findings of licorice and its isolated pure compounds, *G. glabra* extracts (Samadnejad et al. [@CIT0071]) inhibited the formation of TNF in acetic acid-induced ulcerative colitis animal model, 18β-GA (Ishida. 2013) exerted the activity in indomethacin-induced small intestinal damage, *G. uralensis* extracts (Wu et al. [@CIT0088]), 18β-GC (Wang et al. [@CIT0081]), LCE (Lee et al. [@CIT0050]) and DGC (Kim HJ et al. [@CIT0042]) inhibited the formation of TNF in LPS-treated Raw264.7.

MMPs {#s0015}
----

The pathogenic MMPs may lead to joint destruction. In the process of liver fibrosis, the expressions of MMPs are activated by reactive oxygen species and lipid peroxidation products (Poli [@CIT0068]). In periodontal inflammation, MMPs form a family of enzymes that mediate multiple functions both in the tissue destruction and immune responses. The expression and activity of MMPs in noninflamed periodontium is low but is drastically enhanced to pathologically elevated levels due to the dental plaque and infection-induced periodontal inflammation (Sorsa et al. [@CIT0074]). 18α-GC, ISL, LID and LIA all showed up inhibition activities towards MMPS in paraquat poisoning-induced lung injury rat models (Xiao et al. [@CIT0089]), PMA-exposed human umbilical vein endothelial cells (Kang et al. [@CIT0040]) and LPS-induced U937 cells line (La et al. [@CIT0049]) separately.

PGE2 {#s0016}
----

Prostaglandins are potent eicosanoid lipid mediators derived from phospholipase-released arachidonic acid that are involved in numerous homeostatic biological functions and inflammation. They are generated by cyclooxygenase isozymes. The prime mode of prostaglandin is through specific G protein-coupled receptors (Funk [@CIT0023]). In TCM therapeutics, licorice has been used to strengthen the function of digestive system and alleviate pain for thousands of years. *G. uralensis* extract (Wu et al. [@CIT0088]), 18β-GC (Wang et al. [@CIT0081]), 18α-GC (Xie et al. [@CIT0090]), 18β-GA (Wang et al. [@CIT0081]), LCA (Cui et al. [@CIT0012]), LCB (Fu et al. [@CIT0018]), and EC (Fu et al. [@CIT0018]) were all reported to suppress the generation of PGE2 in LPS-treated Raw264.7 macrophages model. PGE2 was reported to activate sensitizing pain receptors and induce fever (Ferreira [@CIT0015]). The inhibition of PGE 2 could explain licorice's ancient characteristics of alleviating pain.

Free radicals {#s0017}
=============

Free radicals, including reactive oxygen species, such as the hydroxyl radical, superoxide anion, and hydrogen peroxide, and reactive nitrogen species, such as NO, are all associated with pathology and cell damage, which have been reported to attack nucleic acids and proteins, as well as unsaturated fatty acids in the cell membrane (Fernández-Moriano et al. [@CIT0016]). In the rheumatoid arthritis, NO has been reported to be an important mediator in the progression of cartilage and bone destruction and induce the production of pathogenic cytokines and chemokines. In liver models, involvement of reactive oxygen species and lipid peroxidation products can be clearly demonstrated in other fundamental events of hepatic fibrogenesis (Poli [@CIT0068]). *Glycyrrhiza uralensis* extract (Wu et al. [@CIT0088]), 18β-GC, 18β-GA (Wang et al. [@CIT0081]), LCA, LCB (Fu et al. [@CIT0018]), LCC (Lee et al. [@CIT0050]), ISL, EC, GLD (Thiyagarajan et al. [@CIT0079]) and DGC (Kim HJ et al. [@CIT0043]), all significantly inhibited the production of free radicals in LPS-treated Raw264.7 macrophages model.

Thus, the underlying anti-inflammatory mechanisms for targeting the related pathogenic factors could explain the extraordinary inhibition properties of licorice.

Drugs that include compounds of licorice {#s0018}
========================================

Drugs came from GC have been successfully used in China and Japan for many years to treat inflammation diseases. Five hundred and fifty-four kinds of drugs containing GC have been approved by the China Food and Drug Administration (CFDA), and four generations of GC preparations have been developed so far, from GC tablets to ammonium glycyrrhizinate, diammonium glycyrrhizinate and magnesium isoglycyrrhizinate (MgIG). The dosage forms are quite abundant, such as extractum, tablet, capsula, injection, granule and oral solution, the main active compounds and preparations have been listed in [Table 4](#t0004){ref-type="table"}. Depending on the clinical researches, MgIG, mainly containing 18α-GC, had a better lipotropy, a higher targeting and fewer adverse reactions, and was regarded as a safer and more effective drug compared with preparations mainly containing 18β-GC (Zeng et al. [@CIT0095]; Xu et al. [@CIT0091]).

###### 

The preparations from licorice approved by CFDA.

  China Approved Drug Names (CADN)                                          Component                                                                                                                                                                               Dosage forms             Batch number   Drug standard code
  ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ -------------- --------------------
  Licorice extract powder                                                   Licorice extract                                                                                                                                                                        Powder                   H65020417      86905972000020
  Bismuth glycyrrhetate powder                                              Bismuth glycyrrhetate                                                                                                                                                                   Powder                   H62021142      86905894000351
  Trisodium glycyrrhetate                                                   Trisodium glycyrrhetate                                                                                                                                                                 Raw material             H65020217      86906000000098
  Glycyrrhetinic acid                                                       Glycyrrhetinic acid                                                                                                                                                                     Raw material             H15021234      86904264000083
  MgIG                                                                      MgIG                                                                                                                                                                                    Raw material             H20051941      86901523001461
  Glycyrrhizic acid A                                                       Glycyrrhizic acid A                                                                                                                                                                     Raw material             H65020210      86906000000081
  Licorzine                                                                 Licorzine                                                                                                                                                                               Raw material             H15021235      86904264000168
  Diammonium glycyrrhizinate                                                Diammonium glycyrrhizinate                                                                                                                                                              Raw material             H20065456      86901375000735
  Dipotassium glycyrrhetate                                                 Dipotassium glycyrrhetate                                                                                                                                                               Raw material             H65020215      86906000000111
  Monopotassium glycyrrhiznate A                                            Monopotassium glycyrrhiznate A                                                                                                                                                          Raw material             H61022582      86902362000219
  Monoammonium glycyrrhizinate S                                            Monoammonium glycyrrhizinate S                                                                                                                                                          Raw material             H20057930      86901498000025
  Potassium glycyrrhefate M                                                 Potassium glycyrrhefate M                                                                                                                                                               Raw material             H20057335      86901498000018
  Mono potassium glycyrrhizinate tablets                                    Mono potassium glycyrrhizinate                                                                                                                                                          Tablets                  Z15021799      86903911000452
  Compound Licorice tablets                                                 Licorice extract, opioid, camphor, star anise oil, sodium benzoate                                                                                                                      Tablets                  Z53020718      86905614002672
  Ephedrine Hydrochloride and Glycyrrhizia Extract Tablets                  Ephedrine hydrochloride, glycyrrhizia extract                                                                                                                                           Tablets                  H61023525      86902503000504
  Compound Glycyrrhizin tablets                                             Glycyrrhizin, glycine and cysteine hydrochloride                                                                                                                                        Tablets                  H20073723      86903094000386
  Compound licorice Aluminium and Magnesium tablets                         Aluminium hydroxide, magnesium trisilicate, magnesium oxide, calcium carbonate, *Bletilla striata*, *Radix aucklandiae*, *Extractum glycyrrhizae liquidum*, Belladonna liquid extract   Tablets                  H42022362      86901984002199
  Diammonium glycyrrhizinate enteric-coated tablets                         Diammonium glycyrrhizinate                                                                                                                                                              Enteric-coated tablets   H20150025      86904797000703
  Extractum glycyrrhizae                                                    Licorice extract                                                                                                                                                                        Extractum                Z61021679      86902331000028
  Licorzine granules                                                        Licorzine                                                                                                                                                                               Granules                 H32022277      86901474000070
  Mono potassium glycyrrhizinate capsule                                    Mono potassium glycyrrhizinate                                                                                                                                                          Capsule                  Z20060085      86904313000217
  Licorzine capsule                                                         Licorzine                                                                                                                                                                               Capsule                  H31022339      86900727000478
  Diammonium glycyrrhizinate capsules                                       Diammonium glycyrrhizinate                                                                                                                                                              Capsules                 H20093489      86901651001531
  Compound glycyrrhizin capsules                                            Glycyrrhizin, glycine and cysteine hydrochloride                                                                                                                                        Capsules                 H20110056      86904152003899
  Compound glycyrrhiza oral solution                                        Extractum glycyrrhizae liquidum, paregoric, glycerinum, guaiamar, concentrated ammonia solution                                                                                         Oral solution            H46020470      86905840001623
  Diammonium glycyrrhizinate for injecton                                   Diammonium glycyrrhizinate                                                                                                                                                              Injection                H20052225      86900151000082
  Compound glycyrrhizin for injection                                       Glycyrrhizin, glycine and cysteine hydrochloride                                                                                                                                        Injection                H20070217      86900234000039
  MgIG injection                                                            MgIG                                                                                                                                                                                    Injection                H20051942      86901523001478
  Compound monoammonium glycyrrhizinate S for injection                     Glycyrrhizin, glycine and cysteine hydrochloride                                                                                                                                        Injection                H20041998      86900356001242
  Diammonium glycyrrhizinate and glucose injection                          Diammonium glycyrrhizinate and glucose                                                                                                                                                  Injection                H20030421      86901523001126
  Diammonium glycyrrhizinate and sodium chloride injection                  Diammonium glycyrrhizinate and sodium chloride                                                                                                                                          Injection                H20010630      86901523001218
  Monoammonium glycyrrhizinate and cysteine and sodium chloride injection   Monoammonium glycyrrhizinate, cysteine and sodium                                                                                                                                       Injection                H22026458      86903282000280

Safety of licorice {#s0019}
==================

Although licorice is considered to be a nontoxic herb in TCM, the safety use of licorice still attached much attention. The mechanisms have been fully evaluated. Licorice was reported to be a competitive inhibitor of 11β-hydroxysteroid dehydrogenases (11β-HSDs), the most important enzymes in the systemic regulation of glucocorticoids and mineralocorticoid (Whorwood et al. [@CIT0087]). There are two 11β-HSDs, 11β-HSD1 and 11β-HSD2. 11β-HSD1 is a bidirectional enzyme that preferred activation of cortisol from cortisone, expressed in liver, adipose, bone and other inflamed tissues. 11β-HSD2 converts active cortisol to inactive cortisone, expressed in the kidney, pancreas and other mineralocorticoid sensitive tissues (Ma et al. [@CIT0060]). GC administration to rats *in vivo* (75 mg·kg^−1^, day for 5 days) resulted in the inhibition of 11β-HSD mRNA levels and 11β-HSD activity in both predominantly mineralocorticoid (kidney and distal colon) and glucocorticoid (liver and pituitary) target tissues, and the inhibition was in a dose-dependent manner *in vitro* (Whorwood et al. [@CIT0087]). In a study conducted in 12 healthy volunteers, the ingestion of 100 g licorice daily for 8 weeks increased the plasma atrial natriuretic peptide concentration and the mean body weight, and decreased the plasma concentrations of antidiuretic hormone, aldosterone and plasma renin activity, which reflected retention of sodium and fluid volume, and the effects were probably due to the mineralocorticoid properties of licorice (Forslund et al. [@CIT0017]). In another case, a 51-year-old lady was diagnosed as acquired apparent mineralocorticoid excess and severe hypertension after eating considerable amounts of salted licorice, while her blood pressure quickly normalized after stopping the intake of the salted licorice (Ruiz-Granados et al. [@CIT0070]).

All of the above reports showed that the hormonal-like effects of licorice might be the main reason for its side effects; hence the particular attention should be attached to the large doses or long-term ingestion of licorice (Wang & Nixon [@CIT0086]). Furthermore, the genetic difference between individuals was also an important reason for different sensitivity, the 11β-HSD2 gene mutation led to lower 11β-HSD2 enzyme activity, and the patients with mutation would be more sensitive than the general population for licorice-induced hypertension. Therefore, the herbal medicine containing licorice may be contraindicated in patients with an 11β-HSD2 mutation (Harahap et al. [@CIT0028]). Although the intake of licorice may have some side effects in humans, all of these side effects were reversible and the health benefits outweigh its side effects with proper control. Instead of raw licorice extract, the compounds isolated from licorice may reduce the GC-induced side effects and improve the therapeutical action.

Conclusions and perspectives {#s0020}
============================

Licorice has been used in TCM for thousands of years to treat inflammatory diseases. The results of this paper showed that 3 triterpenes and 13 flavonoids were mainly responsible for the anti-inflammatory activity of licorice through a variety of mechanisms, especially downregulation of mediators, such as TNF-α, MMPs, PGE2 and oxidative stress on the progression of inflammation-related diseases. In this report, we also reflected the available data on *in vitro* anti-inflammatory activities of licorice and purified compounds on cellular substrates and *in vivo* on animal models. So far, 554 drugs containing natural compounds and derivatives of licorice have been approved by CFDA. As for safety evaluation, licorice was regarded as a competitive inhibitor of 11β-HSDs, long time intake of licorice may lead to acquired apparent mineralocorticoid excess and severe hypertension, furthermore, the genetic difference between individuals was also an important reason for different sensitivity. All the above suggest that licorice could serve as a therapeutic candidate sources for the treatment of inflammatory diseases with a kind consideration of licorice's hormonal-like effects.

A series of licorice compounds have been indicated possessing anti-inflammatory effects. So far, studies focusing on licorice extracts are rather limited, and the active compounds in the extracts are not clear. The single compound, such as 18β-GC has attracted considerably more studies. However, the studies about the interactions of different active compounds are restrained. More importantly, dosage in different models are quite different, more pharmacokinetic studies on licorice using different models should be carried out, and the maximum tolerated dose is also critical for clinical use of licorice and its purified compounds.

Our previous studies showed that the contents of triterpenes and flavonoids varied a lot among three licorice original plants, hence a quite difference will be made among their anti-inflammatory activities, which is worthy of further studies. In addition, total contents of phenols, flavonoids and tannins in licorice varied a lot at different harvest times, the samples obtained during from May and November showed the most favourable free radical scavenging and antioxidant effects, whereas the best gastroprotective effect was observed in the sample obtained during May (Cheel et al. [@CIT0008]). Many compounds, especially the triterpenes, have been developed to the registered drugs of CFDA so far, the side effects of triterpenes have also been investigated for many years. While, the flavonoids of licorice has not been studied deeply, and the large sample, randomized, double-blind and controlled chemoprevention clinical trials about flavonoids are very limited, which require more attention. We can conclude that licorice is a potential source of natural anti-inflammatory agent. However, at the same time, it still needs deeper researches for evaluating its pharmaceutical potentialities and better understanding of its pharmacological mechanisms.
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